<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01531907</url>
  </required_header>
  <id_info>
    <org_study_id>STH16160</org_study_id>
    <nct_id>NCT01531907</nct_id>
  </id_info>
  <brief_title>Relationships Between GLP-2 and Markers of Bone Turnover Following Feeding</brief_title>
  <acronym>GLP-2</acronym>
  <official_title>Relationships Between GLP-2 and Markers of Bone Turnover Following Feeding: the Influence of Obesity and Cellular Mechanisms of Action</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheffield Teaching Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sheffield Teaching Hospitals NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to study differences bone turnover in relation to glucagon-like&#xD;
      peptide-2 (GLP-2) following feeding in lean and obese premenopausal women. Given the&#xD;
      preliminary evidence that GLP-2 may act directly on osteoclasts, the investigators plan to&#xD;
      determine whether GLP2 receptors are expressed in osteoclasts and the effect of GLP-2 on bone&#xD;
      resorption.&#xD;
&#xD;
      Hypotheses:&#xD;
&#xD;
        1. Acute responses of GLP-2 and bone resorption markers following feeding are affected by&#xD;
           body fat mass.&#xD;
&#xD;
        2. Serum levels of GLP-2 are lower in obese pre-menopausal women and are associated with a&#xD;
           reduction in trabecular and/or cortical bone mass&#xD;
&#xD;
        3. GLP-2 has direct actions on osteoclast resorption via a functional receptor&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study objectives:&#xD;
&#xD;
        1. To determine if differences in baseline serum levels of GLP-2 are related to differences&#xD;
           in bone microarchitecture, structure and strength at the distal tibia and distal radius&#xD;
           between obese and lean premenopausal females.&#xD;
&#xD;
        2. To determine whether obesity in premenopausal females influences levels of circulating&#xD;
           GLP-2 following a standardised glucose meal with a resultant change in markers of bone&#xD;
           formation and resorption&#xD;
&#xD;
        3. To test whether GLP-2 directly affects osteoclast function via an identifiable receptor&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 2011</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>GLP-2 levels</measure>
    <time_frame>Change at 20, 60 and 120 minutes</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Osteocalcin levels</measure>
    <time_frame>Change at 20, 60 and 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>β Carboxy-terminal collagen crosslinks (β CTx)levels</measure>
    <time_frame>Change at 20, 60 and 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procollagen 1 N-terminal propeptide (P1NP) levels</measure>
    <time_frame>Change at 20, 60 and 120 minutes</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>High-resolution peripheral quantitative computed tomography (HRpQCT)</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dual-emission X-ray absorptiometry (DXA)</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">19</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese</arm_group_label>
    <description>Premenopausal women, 25 - 40 years with BMI of ≥30kg/m2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lean</arm_group_label>
    <description>Premenopausal women, 25 - 40 years with BMI of 18.5-24.9 kg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Study visit procedures</intervention_name>
    <description>Anthropometric measurements to include:&#xD;
Weight, height, and BMI.&#xD;
Waist and hip circumference&#xD;
Triceps skinfold thickness&#xD;
Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours.</description>
    <arm_group_label>Lean</arm_group_label>
    <arm_group_label>Obese</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      On completion of the study, serum and plasma aliquots will be moved to the Human Tissue&#xD;
      Authority (HTA) licensed biorepository housed in the Centre for Biomedical Research.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The investigators will recruit healthy pre-menopausal, Caucasian female participants 25-40&#xD;
        years and divide them into two groups, obese and lean according to their Body Mass Index.&#xD;
        Participants will be identified and approached from a study group of obese and lean&#xD;
        participants previously recruited for the 'The Effects of Obesity on Bone Structure and&#xD;
        Strength - Fat and Bone Study (FAB)' study (REC ref 10/H1308/61) conducted at the Academic&#xD;
        Unit of Bone Metabolism (AUBM) in Sheffield. Participants from this study have been&#xD;
        selected as some of the scan and neuromuscular function data generated from this study will&#xD;
        be reused as explained below. Body Mass Index ≥30 kg/m2 will be used to define obesity with&#xD;
        BMI for lean participants defined as 18.5-24.9 kg/m2. Thirty participants will be&#xD;
        recruited, 15 obese and 15 lean. Participants will be matched for age, and where possible&#xD;
        height.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 25-40&#xD;
&#xD;
          -  Caucasian&#xD;
&#xD;
          -  Premenopausal&#xD;
&#xD;
          -  Able and willing to consent&#xD;
&#xD;
          -  BMI either 18.5-24.9 kg/m2 or ≥30 kg/m2&#xD;
&#xD;
          -  Completion 'The Effects of Obesity on Bone Structure and Strength' study REC ref&#xD;
             10/H1308/61&#xD;
&#xD;
          -  Consented to be approached for future research studies&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fracture less than twelve months prior to recruitment&#xD;
&#xD;
          -  History of any long term immobilization (duration greater than three months)&#xD;
&#xD;
          -  Current pregnancy or trying to conceive Pregnancy or breast feeding less than one year&#xD;
             prior to recruitment&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  History of or current conditions known to affect bone metabolism, which may include:&#xD;
&#xD;
               -  Diagnosed skeletal disease or osteoarthritis&#xD;
&#xD;
               -  Chronic renal disease&#xD;
&#xD;
               -  Acute or chronic hepatic disease&#xD;
&#xD;
               -  Hyperparathyroidism or Hyperthyroidism&#xD;
&#xD;
               -  Malabsorption syndromes&#xD;
&#xD;
               -  Diagnosed endocrine disorders&#xD;
&#xD;
               -  Diagnosed diabetes mellitus&#xD;
&#xD;
               -  Clinically significant hypocalcemia or hypercalcemia&#xD;
&#xD;
               -  Diagnosed restrictive eating disorder&#xD;
&#xD;
          -  Current or clinically significant previous use of medications or treatment known to&#xD;
             affect bone metabolism, for example:&#xD;
&#xD;
               -  Depot medroxyprogesterone or the combined oral contraceptive pill&#xD;
&#xD;
               -  Glucocorticoid therapy&#xD;
&#xD;
               -  Anti-convulsant therapy&#xD;
&#xD;
               -  Bone treatments (e.g. Bisphosphonates)&#xD;
&#xD;
          -  Alcohol intake of greater than 21 units per week&#xD;
&#xD;
          -  Athlete, defined as an individual participating in competitive sport at amateur or&#xD;
             professional level&#xD;
&#xD;
          -  Monogenic and obesity syndromes&#xD;
&#xD;
          -  History of cancer within the past 5 years excluding skin cancer non melanomas&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul Dimitri, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheffield Childrens Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Academic Unit of Bone Metabolism</name>
      <address>
        <city>Sheffield</city>
        <state>South Yorkshire</state>
        <zip>S5 7AU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 3, 2012</study_first_submitted>
  <study_first_submitted_qc>February 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 13, 2012</study_first_posted>
  <last_update_submitted>February 12, 2019</last_update_submitted>
  <last_update_submitted_qc>February 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 15, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GLP2</keyword>
  <keyword>Obesity</keyword>
  <keyword>Premenopausal</keyword>
  <keyword>Bone</keyword>
  <keyword>Formation</keyword>
  <keyword>Resorption</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

